Opus Genetics, INC. (IRD) — 8-K Filings

All 8-K filings from Opus Genetics, INC.. Browse 28 Current Event Report reports with AI-powered summaries and risk analysis.

8-K Filings (28)

8-K Filing — Apr 24, 2026
8-K Filing — Apr 22, 2026
8-K Filing — Apr 7, 2026
Opus Genetics Relocates Principal Executive Offices — Dec 19, 2025 Risk: low
Opus Genetics, Inc. filed an 8-K on December 19, 2025, reporting an event on December 17, 2025. The filing indicates a change in the company's principal executi
Opus Genetics Files 8-K — Nov 6, 2025 Risk: low
Opus Genetics, Inc. filed an 8-K on November 6, 2025, reporting on other events and financial statements. The company, formerly known as Ocuphire Pharma, Inc.,
Opus Genetics Files 8-K with Regulatory Updates — Sep 30, 2025 Risk: low
Opus Genetics, Inc. filed an 8-K on September 30, 2025, reporting on events that occurred on the same date. The filing includes information related to Regulatio
Opus Genetics Files 8-K on Officer/Director Changes — Sep 2, 2025 Risk: medium
Opus Genetics, Inc. filed an 8-K on August 29, 2025, reporting on the departure of directors or certain officers, election of directors, appointment of certain
Opus Genetics Reports Unregistered Equity Sales — Aug 25, 2025 Risk: medium
Opus Genetics, Inc. filed an 8-K on August 25, 2025, reporting unregistered sales of equity securities. The filing does not specify the number of shares sold or
Opus Genetics Enters Material Definitive Agreement — Jul 23, 2025 Risk: medium
On July 22, 2025, Opus Genetics, Inc. entered into a material definitive agreement. The filing also includes information regarding Regulation FD disclosure and
Opus Genetics Files 8-K — Jun 26, 2025 Risk: low
Opus Genetics, Inc. filed an 8-K on June 26, 2025, reporting "Other Events" and "Financial Statements and Exhibits." The filing does not contain specific detail
Opus Genetics Files 8-K on Leadership and Compensation Changes — Jun 25, 2025 Risk: medium
On June 25, 2025, Opus Genetics, Inc. filed an 8-K report detailing changes in its board of directors and executive compensation arrangements. The filing indica
Opus Genetics Files 8-K: Reg FD & Financials — Jun 23, 2025 Risk: low
On June 23, 2025, Opus Genetics, Inc. filed an 8-K report. The filing primarily concerns Regulation FD disclosures and financial statements and exhibits. The co
Opus Genetics Enters Material Definitive Agreement — Jun 20, 2025 Risk: medium
On June 13, 2025, Opus Genetics, Inc. entered into a material definitive agreement. The company, formerly known as Ocuphire Pharma, Inc. and Rexahn Pharmaceutic
Opus Genetics Files 8-K on Shareholder Vote Matters — May 1, 2025 Risk: low
Opus Genetics, Inc. filed an 8-K on May 1, 2025, reporting on matters submitted to a vote of security holders as of April 30, 2025. The filing does not contain
Opus Genetics Terminates Material Definitive Agreement — Apr 4, 2025 Risk: medium
Opus Genetics, Inc. announced on April 2, 2025, the termination of a material definitive agreement. The company, formerly known as Ocuphire Pharma, Inc., filed
Opus Genetics Files 8-K on Equity Sales — Mar 24, 2025 Risk: medium
Opus Genetics, Inc. filed an 8-K on March 24, 2025, reporting unregistered sales of equity securities and other events. The filing also includes financial state
Opus Genetics Files 8-K on Operations — Mar 20, 2025 Risk: low
Opus Genetics, Inc. filed an 8-K on March 20, 2025, reporting on its results of operations and financial condition. The filing indicates the company's principal
Opus Genetics Files 8-K for Bylaw Amendments & Financials — Mar 20, 2025 Risk: low
On March 19, 2025, Opus Genetics, Inc. filed an 8-K report. The filing primarily concerns amendments to its Articles of Incorporation or Bylaws, other events, a
Opus Genetics Files 8-K for Other Events — Mar 4, 2025 Risk: medium
Opus Genetics, Inc. filed an 8-K on March 4, 2025, reporting "Other Events." The filing does not contain specific details about the nature of these events, doll
Opus Genetics Announces Board and Executive Changes — Jan 24, 2025 Risk: medium
Opus Genetics, Inc. announced on January 17, 2025, changes related to its board of directors and executive compensation. The filing details the departure of cer
Opus Genetics (fka Ocuphire Pharma) Files 8-K — Jan 23, 2025 Risk: low
On January 23, 2025, Opus Genetics, Inc. filed an 8-K report. The filing indicates that the company's former name was Ocuphire Pharma, Inc., with a name change
Opus Genetics Files 8-K — Jan 14, 2025 Risk: low
Opus Genetics, Inc. filed an 8-K on January 14, 2025, reporting "Other Events" and "Financial Statements and Exhibits" as of January 13, 2025. The company, form
Ocuphire Pharma Acquired by Lumina Acquisition Corp. — Oct 22, 2024 Risk: medium
Ocuphire Pharma, Inc. announced on October 22, 2024, the completion of its acquisition by Lumina Acquisition Corp. The transaction, which was previously announc
Ocuphire Pharma Files 8-K with Corporate Updates — Jun 13, 2024 Risk: low
Ocuphire Pharma, Inc. filed an 8-K on June 13, 2024, reporting events that occurred on June 11, 2024. The filing indicates changes related to the company's arti
Ocuphire Pharma Files 8-K on Operations and Financials — May 10, 2024 Risk: low
Ocuphire Pharma, Inc. filed an 8-K on May 10, 2024, reporting on its results of operations and financial condition. The filing also includes financial statement
Ocuphire Pharma Appoints New Director — Apr 17, 2024 Risk: low
Ocuphire Pharma, Inc. announced on April 11, 2024, a change in its board of directors. Specifically, Dr. Robert L. Van Sickle has been appointed to the Board of
Ocuphire Pharma Files 8-K for Disclosure and Exhibits — Mar 27, 2024 Risk: low
Ocuphire Pharma, Inc. filed an 8-K on March 27, 2024, to report a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain sp
Ocuphire Pharma Reports Officer Compensation Changes — Feb 16, 2024 Risk: medium
Ocuphire Pharma, Inc. filed an 8-K on February 16, 2024, reporting an event that occurred on February 12, 2024. The filing pertains to changes in compensatory a

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX